#vaccinedevelopment #ErVimmune #biotech #cancervaccine #readytousevaccine #personalisedvaccines #celltherapies #cancervaccines #cancervaccinecandidate #ErVac01 #immunotherapies #coldtumours #triplenegativebreastcancer #ovariancancer #offtheshelfcancervaccine #difficulttotreatcancers
zurl.co/Z94ou
zurl.co/Z94ou
ErVimmune raises 17m euros in funding to develop cancer vaccine - PharmaTimes
The vaccine could be created as a ready-to-use product, rather than needing to be personalised
pharmatimes.com
January 28, 2026 at 9:18 AM
👉 CAR‑T & TIL therapies are reshaping oncology — but their toxicities bring new challenges. Join our #ESMOOnAir webinar to learn practical strategies to recognise & manage them
🔗 Register: https://ow.ly/nP0x50XZYwC
#ESMOWebinar #celltherapies
🔗 Register: https://ow.ly/nP0x50XZYwC
#ESMOWebinar #celltherapies
January 20, 2026 at 3:01 PM
👉 CAR‑T & TIL therapies are reshaping oncology — but their toxicities bring new challenges. Join our #ESMOOnAir webinar to learn practical strategies to recognise & manage them
🔗 Register: https://ow.ly/nP0x50XZYwC
#ESMOWebinar #celltherapies
🔗 Register: https://ow.ly/nP0x50XZYwC
#ESMOWebinar #celltherapies
@cgtcatapult.bsky.social has announced a new consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells could be applied to a range of a #CellTherapies 🧪
Learn more ➡️ https://loom.ly/dAewfh4
Learn more ➡️ https://loom.ly/dAewfh4
December 30, 2025 at 10:01 AM
@cgtcatapult.bsky.social has announced a new consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells could be applied to a range of a #CellTherapies 🧪
Learn more ➡️ https://loom.ly/dAewfh4
Learn more ➡️ https://loom.ly/dAewfh4
Join the WPC for a special live webinar exploring dopamine cell therapies for Parkinson’s disease.
Date: Wednesday, Dec 3, 2025
Time: 8AM CT/ 9AM ET/3PM CET
Program made possible w/ support from BlueRock Therapeutics
Learn More: www.worldpdcoalition.org/celltherapies
#Parkinsons #CellTherapy
Date: Wednesday, Dec 3, 2025
Time: 8AM CT/ 9AM ET/3PM CET
Program made possible w/ support from BlueRock Therapeutics
Learn More: www.worldpdcoalition.org/celltherapies
#Parkinsons #CellTherapy
November 12, 2025 at 5:15 PM
Join the WPC for a special live webinar exploring dopamine cell therapies for Parkinson’s disease.
Date: Wednesday, Dec 3, 2025
Time: 8AM CT/ 9AM ET/3PM CET
Program made possible w/ support from BlueRock Therapeutics
Learn More: www.worldpdcoalition.org/celltherapies
#Parkinsons #CellTherapy
Date: Wednesday, Dec 3, 2025
Time: 8AM CT/ 9AM ET/3PM CET
Program made possible w/ support from BlueRock Therapeutics
Learn More: www.worldpdcoalition.org/celltherapies
#Parkinsons #CellTherapy
What is the timeline for cell therapies?
By. Dr. @amarkelkar
#BloodCancersOncTalk2025 #BloodCancer #CancerGRACE #CancerEducation #CellTherapies
By. Dr. @amarkelkar
#BloodCancersOncTalk2025 #BloodCancer #CancerGRACE #CancerEducation #CellTherapies
October 25, 2025 at 4:39 PM
What is the timeline for cell therapies?
By. Dr. @amarkelkar
#BloodCancersOncTalk2025 #BloodCancer #CancerGRACE #CancerEducation #CellTherapies
By. Dr. @amarkelkar
#BloodCancersOncTalk2025 #BloodCancer #CancerGRACE #CancerEducation #CellTherapies
Now presenting Dr. @amarkelkar: "The Future of Medicine is Now: Emerging Cell Therapies"
#BloodCancersOncTalk #CellTherapies #CarTCell #BloodCancerEducation
#BloodCancersOncTalk #CellTherapies #CarTCell #BloodCancerEducation
October 25, 2025 at 4:35 PM
Now presenting Dr. @amarkelkar: "The Future of Medicine is Now: Emerging Cell Therapies"
#BloodCancersOncTalk #CellTherapies #CarTCell #BloodCancerEducation
#BloodCancersOncTalk #CellTherapies #CarTCell #BloodCancerEducation
GeneNovate is the first nationwide entrepreneurship program in Germany, designed to empower innovators/ entrepreneurs in the field of Gene and #CellTherapies, #Biotech, Medicine Health and Life Science.
The #GeneNovate program runs from 12/25 to 06/26.
www.nationale-strategie-gct.de/genenovate/c...
The #GeneNovate program runs from 12/25 to 06/26.
www.nationale-strategie-gct.de/genenovate/c...
October 15, 2025 at 12:12 PM
GeneNovate is the first nationwide entrepreneurship program in Germany, designed to empower innovators/ entrepreneurs in the field of Gene and #CellTherapies, #Biotech, Medicine Health and Life Science.
The #GeneNovate program runs from 12/25 to 06/26.
www.nationale-strategie-gct.de/genenovate/c...
The #GeneNovate program runs from 12/25 to 06/26.
www.nationale-strategie-gct.de/genenovate/c...
Kenai Therapeutics is on a mission to cure neurological conditions like #Parkinsons using #celltherapies. Nick Manusos, CEO of Kenai, joined The Bio Hub to share his path to Kenai, and the lessons he learned along the way. #SaiseiPortCo @kenaitx.bsky.social
Listen here: bit.ly/42aLMSY
Listen here: bit.ly/42aLMSY
The BioHub - The Avetix Podcast - S2 Ep71 - Nick Manusos - CEO of Kenai Therapeutics
Welcome back to another episode of The BioHub, we were delighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patients with Parkinson’s disease. He holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem cell therapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.
bit.ly
September 25, 2025 at 2:58 PM
Kenai Therapeutics is on a mission to cure neurological conditions like #Parkinsons using #celltherapies. Nick Manusos, CEO of Kenai, joined The Bio Hub to share his path to Kenai, and the lessons he learned along the way. #SaiseiPortCo @kenaitx.bsky.social
Listen here: bit.ly/42aLMSY
Listen here: bit.ly/42aLMSY
NU25 - Day 2
'Cord blood derived cell therapies for preterm brain injury'
Professor @atulmalhotra.bsky.social Monash Children's Hospital and @monashuniversity.bsky.social
Register today bit.ly/NeonatalUpda...
@ebneo.bsky.social @espr-esn.bsky.social
#neonataology #CellTherapies #NeuroScience
'Cord blood derived cell therapies for preterm brain injury'
Professor @atulmalhotra.bsky.social Monash Children's Hospital and @monashuniversity.bsky.social
Register today bit.ly/NeonatalUpda...
@ebneo.bsky.social @espr-esn.bsky.social
#neonataology #CellTherapies #NeuroScience
September 24, 2025 at 12:22 PM
NU25 - Day 2
'Cord blood derived cell therapies for preterm brain injury'
Professor @atulmalhotra.bsky.social Monash Children's Hospital and @monashuniversity.bsky.social
Register today bit.ly/NeonatalUpda...
@ebneo.bsky.social @espr-esn.bsky.social
#neonataology #CellTherapies #NeuroScience
'Cord blood derived cell therapies for preterm brain injury'
Professor @atulmalhotra.bsky.social Monash Children's Hospital and @monashuniversity.bsky.social
Register today bit.ly/NeonatalUpda...
@ebneo.bsky.social @espr-esn.bsky.social
#neonataology #CellTherapies #NeuroScience
Heute feierten wir gemeinsam mit der #Charité, der #Bayer AG & der Politik den Spatenstich für das Berlin Center for #Gene and #CellTherapies (BCGCT). Es wird #Forschung, Entwicklung & Produktion vereinen & die Entwicklung von neuartigen Arzneimitteln beschleunigen. www.bihealth.org/de/aktuell/m...
September 16, 2025 at 12:52 PM
Heute feierten wir gemeinsam mit der #Charité, der #Bayer AG & der Politik den Spatenstich für das Berlin Center for #Gene and #CellTherapies (BCGCT). Es wird #Forschung, Entwicklung & Produktion vereinen & die Entwicklung von neuartigen Arzneimitteln beschleunigen. www.bihealth.org/de/aktuell/m...
One of the most exciting developments is the rise of #CellTherapies for #neurodegenerative diseases. What excites me most is the collaboration needed between regulators, scientists, and biopharma to bring these innovations safely to patients. Getting this right could transform neurological care.
September 11, 2025 at 1:31 PM
One of the most exciting developments is the rise of #CellTherapies for #neurodegenerative diseases. What excites me most is the collaboration needed between regulators, scientists, and biopharma to bring these innovations safely to patients. Getting this right could transform neurological care.
Learn more about our exciting collaboration with Plurify to develop technology that improves the purity of #CellTherapies - making them safer, more efficacious and less costly to produce 👇
The @innovateuk.bsky.social Catapult Network, is proud to support #UKBusinesses - just like this powerful partnership between Plurify and the @cgtcatapult.bsky.social ! 🧬🪴
August 7, 2025 at 3:03 PM
Learn more about our exciting collaboration with Plurify to develop technology that improves the purity of #CellTherapies - making them safer, more efficacious and less costly to produce 👇
Due aziende biotech uniscono le forze per portare terapie innovative ai pazienti affetti da epidermolisi bollosa e ulcere venose croniche.
𝐓𝐮𝐭𝐭𝐞 𝐥𝐞 𝐢𝐧𝐟𝐨:
👉 www.osservatorioterapieavanzate.it/terapie-avan...
#celltherapies #Epidermolysisbullosa
𝐓𝐮𝐭𝐭𝐞 𝐥𝐞 𝐢𝐧𝐟𝐨:
👉 www.osservatorioterapieavanzate.it/terapie-avan...
#celltherapies #Epidermolysisbullosa
June 25, 2025 at 9:57 AM
Due aziende biotech uniscono le forze per portare terapie innovative ai pazienti affetti da epidermolisi bollosa e ulcere venose croniche.
𝐓𝐮𝐭𝐭𝐞 𝐥𝐞 𝐢𝐧𝐟𝐨:
👉 www.osservatorioterapieavanzate.it/terapie-avan...
#celltherapies #Epidermolysisbullosa
𝐓𝐮𝐭𝐭𝐞 𝐥𝐞 𝐢𝐧𝐟𝐨:
👉 www.osservatorioterapieavanzate.it/terapie-avan...
#celltherapies #Epidermolysisbullosa
🚀 Kick-off: Thymus-on-Chip #EUROSTARS Project!
Together with Genewity B.V. & PyroScience GmbH, we’re developing the world’s first #Thymus-on-chip platform — paving the way for more effective #CellTherapies, #DrugTesting, & #BiomedicalResearch!💉💊 Excited to push boundaries with this fantastic team! 🚀
Together with Genewity B.V. & PyroScience GmbH, we’re developing the world’s first #Thymus-on-chip platform — paving the way for more effective #CellTherapies, #DrugTesting, & #BiomedicalResearch!💉💊 Excited to push boundaries with this fantastic team! 🚀
June 2, 2025 at 10:30 AM
🚀 Kick-off: Thymus-on-Chip #EUROSTARS Project!
Together with Genewity B.V. & PyroScience GmbH, we’re developing the world’s first #Thymus-on-chip platform — paving the way for more effective #CellTherapies, #DrugTesting, & #BiomedicalResearch!💉💊 Excited to push boundaries with this fantastic team! 🚀
Together with Genewity B.V. & PyroScience GmbH, we’re developing the world’s first #Thymus-on-chip platform — paving the way for more effective #CellTherapies, #DrugTesting, & #BiomedicalResearch!💉💊 Excited to push boundaries with this fantastic team! 🚀
While it is still early days for CGTs in #autoimmunedisease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift #celltherapies to new heights, but it could redefine them entirely. 🧪🧬⑂ #SciComm
Shooting for immune
While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only co...
www.cellgenetherapyreview.com
May 19, 2025 at 3:46 PM
While it is still early days for CGTs in #autoimmunedisease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift #celltherapies to new heights, but it could redefine them entirely. 🧪🧬⑂ #SciComm
🧬 Bilan de l’atelier #IMS 2025 à #Boston
Nouveaux développements dans le domaine de l’ #ImmunoThérapie du #MyélomeMultiple
Les 28 et 29 mars s’est tenu à Boston « l'Immune Effector #CellTherapies in Multiple #Myeloma » de l’International Myeloma Society.
#CAR-Tcells
www.ukw.de/aktuelle-mel...
Nouveaux développements dans le domaine de l’ #ImmunoThérapie du #MyélomeMultiple
Les 28 et 29 mars s’est tenu à Boston « l'Immune Effector #CellTherapies in Multiple #Myeloma » de l’International Myeloma Society.
#CAR-Tcells
www.ukw.de/aktuelle-mel...
#myelomonline #multiplesmyelom #immuntherapie #forschung2025 #cartzell… | Myelom.Online e.V.
🧬 Rückblick auf den IMS-Workshop 2025 in Boston 🇺🇸
Neue Entwicklungen in der Immuntherapie beim Multiplen Myelom
Vom 28.–29. März fand in Boston der internationale Workshop „Immune Effector Cell Ther...
www.linkedin.com
May 16, 2025 at 6:55 PM
🧬 Bilan de l’atelier #IMS 2025 à #Boston
Nouveaux développements dans le domaine de l’ #ImmunoThérapie du #MyélomeMultiple
Les 28 et 29 mars s’est tenu à Boston « l'Immune Effector #CellTherapies in Multiple #Myeloma » de l’International Myeloma Society.
#CAR-Tcells
www.ukw.de/aktuelle-mel...
Nouveaux développements dans le domaine de l’ #ImmunoThérapie du #MyélomeMultiple
Les 28 et 29 mars s’est tenu à Boston « l'Immune Effector #CellTherapies in Multiple #Myeloma » de l’International Myeloma Society.
#CAR-Tcells
www.ukw.de/aktuelle-mel...
Why test #celltherapies one-by-one when you can use multiplexed #SynBio #proteinengineering & #ML to design, measure & track them at scale?
The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!
More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏
The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!
More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏
April 29, 2025 at 11:01 PM
Why test #celltherapies one-by-one when you can use multiplexed #SynBio #proteinengineering & #ML to design, measure & track them at scale?
The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!
More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏
The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!
More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏
Join us in Bruges at the #INCI25 to discuss more about novel #celltherapies to treat #cancer
Last chance to register!
🔗 vibbio.tech/INCI25
Last chance to register!
🔗 vibbio.tech/INCI25
Immune Niches in Cancer & Inflammation
7-9 May 2025, Bruges, Belgium Organized in partnership with Cell Press
vibbio.tech
April 22, 2025 at 12:58 PM
Join us in Bruges at the #INCI25 to discuss more about novel #celltherapies to treat #cancer
Last chance to register!
🔗 vibbio.tech/INCI25
Last chance to register!
🔗 vibbio.tech/INCI25
(2/2) This work emphasizes the need to better understand genetic variants in human pluripotent #StemCells, which play a crucial role in the advancement of #CellTherapies.
Congrats to the authors, including SCN’s Vice-President, Research & Training, Jon Draper, on this significant publication! 👏
Congrats to the authors, including SCN’s Vice-President, Research & Training, Jon Draper, on this significant publication! 👏
April 4, 2025 at 7:24 PM
(2/2) This work emphasizes the need to better understand genetic variants in human pluripotent #StemCells, which play a crucial role in the advancement of #CellTherapies.
Congrats to the authors, including SCN’s Vice-President, Research & Training, Jon Draper, on this significant publication! 👏
Congrats to the authors, including SCN’s Vice-President, Research & Training, Jon Draper, on this significant publication! 👏
#Observationalstudies #interventionaltrials #celltherapies #genetherapies #AI #clinicaltrials #integratedendtoendtrials #DCTmodels #interventionaltrialdesigns #digitaltechnologies #patientparticipation #virtualobservationalstudies #hybridobservationalstudies
pharmaphorum.com/patients/uni...
pharmaphorum.com/patients/uni...
Unifying observational research with a next-generation virtual approach
Explore the unification of observational research with a next-generation virtual approach in decentralised clinical trials (DCTs). Learn more about the benefits and advancements in this innovative met...
pharmaphorum.com
April 4, 2025 at 9:31 AM
#PortfolioNewsI We're proud to share that we've joined the oversubscribed $102M financing of our #portfolio company #NeuronaTherapeutics
🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders
👉 buff.ly/YHqiseP
#vc #CNS
🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders
👉 buff.ly/YHqiseP
#vc #CNS
April 4, 2025 at 8:26 AM
#PortfolioNewsI We're proud to share that we've joined the oversubscribed $102M financing of our #portfolio company #NeuronaTherapeutics
🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders
👉 buff.ly/YHqiseP
#vc #CNS
🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders
👉 buff.ly/YHqiseP
#vc #CNS
At our free #webinar on March 20th from 12-1pm ET, LyGenesis co-Founder and CEO Michael Hufford, PhD, will discuss how his company is supporting #longevity through #Celltherapies for #organregeneration and #transplant.
Learn more & RSVP here: bit.ly/41l5slH
Learn more & RSVP here: bit.ly/41l5slH
March 7, 2025 at 7:58 PM
At our free #webinar on March 20th from 12-1pm ET, LyGenesis co-Founder and CEO Michael Hufford, PhD, will discuss how his company is supporting #longevity through #Celltherapies for #organregeneration and #transplant.
Learn more & RSVP here: bit.ly/41l5slH
Learn more & RSVP here: bit.ly/41l5slH
Cell and Gene Therapy 2025, hosted by Technology Networks and sponsored by Sino Biological, is happening online on March 19-20. Explore the latest in #GenomeEditing, novel delivery vectors, and allogeneic #CellTherapies. Free registration!
🔗 ow.ly/Wa2450V7cPY
🔗 ow.ly/Wa2450V7cPY
Cell and Gene Therapy 2025
This event will focus on the latest progress in precision genome editing, novel delivery vectors, allogeneic cell therapies and the journey from laboratory research to clinical application, offering i...
ow.ly
February 26, 2025 at 9:22 PM
Cell and Gene Therapy 2025, hosted by Technology Networks and sponsored by Sino Biological, is happening online on March 19-20. Explore the latest in #GenomeEditing, novel delivery vectors, and allogeneic #CellTherapies. Free registration!
🔗 ow.ly/Wa2450V7cPY
🔗 ow.ly/Wa2450V7cPY
Bringing new therapy to patients needs strong clinical trials and regulatory alignment. Europe is updating GCP guidelines (ICH E6(R3)) to boost efficiency while ensuring safety and transparency
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop
February 20, 2025 at 11:24 AM
Bringing new therapy to patients needs strong clinical trials and regulatory alignment. Europe is updating GCP guidelines (ICH E6(R3)) to boost efficiency while ensuring safety and transparency
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop
Our CEO, Tim Lu, MD, PhD, spoke with @benmcomer.bsky.social at Life Science Leader to share insights on how we plan to improve #celltherapies in oncology utilizing our logic gating technology to pinpoint diseased cells and spare healthy ones. Thanks so much for including us! #SNTI bit.ly/3Et3zM4
Companies To Watch: Senti Bio
<p>Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.</p>
bit.ly
February 6, 2025 at 5:24 PM
Our CEO, Tim Lu, MD, PhD, spoke with @benmcomer.bsky.social at Life Science Leader to share insights on how we plan to improve #celltherapies in oncology utilizing our logic gating technology to pinpoint diseased cells and spare healthy ones. Thanks so much for including us! #SNTI bit.ly/3Et3zM4